Sermorelin Acetate — Peptide Protocol Wiki reference
patient_educationexpert_opinion · status: needs_provider_reviewDetails
Summary (generated — provider review required)
Sermorelin: GHRH Analog Research Guide | Peptide Protocol Wiki Skip to main content 🧬 Peptide Protocol Wiki Peptides Side Effects New Learn Directory Tools Blog News About ⌘K ⌘K 🌱 New to Peptides? Start the 7-step beginner guide Peptides Side Effects New Directory Learn Tools Blog News About Sermorelin 📋 Overview 🧬 Molecule 🔄 Similar ⚠️ Side Effects 💉 Dosing 🔬 Research 🚨 Risks 👥 Community 📊 Community Data Home Peptides Sermorelin Growth Hormone Anti-Aging & Longevity approved Sermorelin Also known as: GRF 1-29, GHRH(1-29), Geref, Sermorelin Acetate Compare with 3 peptide s Research compiled by Peptide Protocol Wiki 📅 Updated February 8, 2026 Citations Verified TL;DR Sermorelin is a synthetic 29-amino acid peptide corresponding to the first 29 amino acids of endogenous GHRH (growth hormone-releasing hormone). It was previously FDA-approved (as Geref) for diagnostic evaluation and treatment of GH deficiency and stimulates GH release from the pituitary via the GHRH receptor.
The original source document remains the source of truth. Generated summaries are not authoritative.
Linked assets (19) · phenotypes (0)
evidence_reference, safety_reference, dosing_reference, contraindication_reference, mechanism
Findings (65) · awaiting review (44)
regulatory · pending
Its off-label prescribing is not restricted by federal law, unlike recombinant hGH which is subject to specific legal limitations on off-label use.
safety · pending
Sermorelin: GHRH Analog Research Guide | Peptide Protocol Wiki Skip to main content 🧬 Peptide Protocol Wiki Peptides Side Effects New Learn Directory Tools Blog News About ⌘K ⌘K 🌱 New to Peptides?
dosing · pending
Start the 7-step beginner guide Peptides Side Effects New Directory Learn Tools Blog News About Sermorelin 📋 Overview 🧬 Molecule 🔄 Similar ⚠️ Side Effects 💉 Dosing 🔬 Research 🚨 Risks 👥 Community 📊 Community Data Home Peptides Sermorelin Growth Hormone Anti-Aging & Longevity approved Sermorelin Also known as: GRF 1-29, GHRH(1-29), Geref, Sermorelin Acetate Compare with 3 peptide s Research compiled by Peptide Protocol Wiki 📅 Updated February 8, 2026 Citations Verified TL;DR Sermorelin is a synthetic 29-amino acid peptide corresponding to the first 29 amino acids of endogenous GHRH (growth hormone-releasing hormone).
regulatory · pending
It was previously FDA-approved (as Geref) for diagnostic evaluation and treatment of GH deficiency and stimulates GH release from the pituitary via the GHRH receptor.
safety · pending
Browse all growth hormone peptides → Table of Contents 📌 TL;DR • Stimulates endogenous GH release through the physiological GHRH receptor • Previously FDA-approved for GH deficiency diagnosis (Geref) • Maintains normal GH pulsatility and feedback mechanisms • Synergistic effects when combined with GHRP peptides like ipamorelin Community-Reported Side Effects Anecdotal ?
dosing · pending
📋 Protocol Quick-Reference Growth hormone stimulation for anti-aging, body composition, and sleep quality improvement 💉 Dosing Amount 200-300 mcg Frequency Once daily at bedtime, 5 nights per week Duration 3-6 months, cyclical (on/off periods) 💊 Administration Route SC Schedule Once daily at bedtime, 5 nights per week Timing 30 minutes before bedtime on an empty stomach (minimum 90-minute fast before injection) ✓ Rotate injection sites 📅 Cycle Duration 3-6 months, cyclical (on/off periods) Repeatable Yes Preparation & Storage Diluent: Bacteriostatic water Use within: 14 days Storage: Store lyophilized powder at controlled room temperature (20-25C) or refrigerated (2-8C).
outcome · pending
Long-term administration of GHRH(1-29)NH2 in elderly subjects demonstrated increases in IGF-1 levels, lean body mass, and improvements in certain markers of body composition.
dosing · pending
⚗️ Suggested Bloodwork ( 6 tests) IGF-1 When: Baseline Why: Primary marker for GH axis function; guides dose titration GH stimulation test (optional) When: Baseline Why: Confirm pituitary somatotroph function Fasting glucose and HbA1c When: Baseline Why: GH stimulation can worsen insulin resistance Thyroid panel (TSH, free T3, free T4) When: Baseline Why: Thyroid status affects GH response; hypothyroidism blunts GHRH effect CMP with liver enzymes When: Baseline Why: Baseline organ function Lipid panel When: Baseline Why: GH optimization can improve lipid profile 💡 Key Considerations → Bedtime injection aligns with natural nocturn
contraindication · pending
al GH pulse → Often combined with ipamorelin (100-300 mcg) for synergistic GHRH+GHRP effect → 5 days on, 2 days off is a common schedule to prevent desensitization → Obesity reduces GH response and may require higher doses → Contraindication: Avoid with active malignancy or history of cancer; caution in diabetes; not for use with active intracranial lesions Subscribe to unlock this content Get weekly peptide research summaries, new study alerts, and protocol updates — free.
dosing · pending
Fat loss, muscle growth, healing, anti-aging, and cognitive stacks with evidence levels, dosing timing, and safety considerations.
outcome · pending
Restore access No thanks, continue reading Related Reading Peptide Ipamorelin selective growth hormone secretagogue Peptide Tesamorelin GHRH analog peptide Peptide CJC-1295 No DAC (Mod GRF 1-29) GHRH analog How Sermorelin works at the cellular level Overview of Sermorelin benefits and applications Scientific Details Molecular Formula C149H246N44O42S Molecular Weight 3357.88 Da CAS Number 86168-78-7 Sequence Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2 What is Sermorelin?
mechanism · pending
he GHRH receptor.
regulatory · pending
Sermorelin was developed as a diagnostic and therapeutic agent for growth hormone deficiency and was approved by the U.S.
regulatory · pending
FDA in 1997 under the brand name Geref.
mechanism · pending
This physiological approach preserves the normal pulsatile pattern of GH release and is regulated by the inhibitory feedback of somatostatin, making overdose essentially impossible through this mechanism.
mechanism · pending
Mechanism of Action # Sermorelin binds to the GHRH receptor (GHRH-R) on somatotroph cells in the anterior pituitary gland.
outcome · pending
reactivate quiescent somatotrophs and increase pituitary GH reserve.
mechanism · pending
Walker (2006) proposed that sermorelin may represent a better approach to management of adult-onset growth hormone insufficiency compared to rhGH, citing its physiological mechanism, lower risk profile, and preservation of the neuroendocrine feedback axis.
outcome · pending
This G-protein-coupled receptor activation triggers a cascade of intracellular signaling events: GHRH receptor binding : Sermorelin binds with high specificity to GHRH-R on pituitary somatotrophs cAMP pathway activation : Receptor activation stimulates adenylyl cyclase, increasing intracellular cyclic AMP (cAMP) levels GH gene transcription : Elevated cAMP activates protein kinase A (PKA), which phosphorylates the transcription factor CREB, upregulating GH messenger RNA transcription GH vesicle exocytosis : Calcium influx through voltage-gated calcium channels triggers release of stored GH granules Pituitary reserve enhancement : Chronic stimulation increases pituitary GH mRNA content and somatotroph responsiveness A key advantage of sermorelin over exogenous GH administrat
outcome · pending
ion is that it stimulates pituitary gene transcription of hGH messenger RNA, thereby increasing pituitary reserve.
mechanism · pending
This mechanism helps preserve the growth hormone neuroendocrine axis, which is typically the first endocrine axis to decline during aging.
outcome · pending
When GH and IGF-1 levels rise, somatostatin release from the hypothalamus increases, suppressing further GH release.
safety · pending
This self-regulating mechanism prevents supraphysiological GH levels and reduces the risk of adverse effects associated with exogenous GH administration.
regulatory · pending
Clinical History and Regulatory Status # Sermorelin has a well-documented clinical history spanning several decades: 1980s : GHRH(1-29) was synthesized and characterized as the minimal active fragment of GHRH 1997 : FDA approved sermorelin acetate (Geref Diagnostic) for evaluation of pituitary GH secretory capacity 1997 : FDA also approved Geref for treatment of idiopathic growth hormone deficiency in children 2008 : Sermorelin products were voluntarily withdrawn from the U.S.
safety · pending
market due to manufacturing difficulties with the active pharmaceutical ingredient, not due to safety concerns The withdrawal was purely supply-related, and sermorelin continues to be available through compounding pharmacies in the United States.
dosing · pending
The sermorelin stimulation test involves: Intravenous administration of sermorelin at 1 mcg/kg body weight Serial blood sampling for GH levels at 15, 30, 45, and 60 minutes post-injection A normal response (GH peak above 7-10 ng/mL) indicates intact pituitary somatotroph function A blunted response suggests pituitary-level dysfunction This test proved more specific than other provocative GH tests, with fewer false-positive results in children without true GH deficiency.
dosing · pending
Effects on Growth in Children # Clinical studies demonstrated that once-daily subcutaneous sermorelin at 30 mcg/kg body weight, administered at bedtime, effectively promotes growth in prepubertal children with idiopathic GH deficiency.
outcome · pending
Treatment resulted in significant increases in height velocity that were sustained over 12 months, and sermorelin induced catch-up growth in the majority of GH-deficient children studied.
outcome · pending
The rationale for combination therapy is based on the synergistic interaction between GHRH and GHRP pathways: GHRH pathway (sermorelin) : Stimulates GH synthesis and release via cAMP/PKA GHRP/ghrelin pathway (ipamorelin, GHRP-2) : Stimulates GH release via the GHS-R1a receptor, also suppresses somatostatin When administered together, the GH response is substantially greater than either agent alone, as the two pathways amplify each other while simultaneously reducing somatostatin-mediated inhibition.
dosing · pending
Evidence Gaps and Limitations # Despite its former FDA-approved status, several knowledge gaps remain: Long-term outcomes of sermorelin therapy in aging adults lack robust randomized controlled trial data Optimal dosing regimens for anti-aging applications have not been established through definitive clinical trials Head-to-head comparisons with tesamorelin (another GHRH analog currently FDA-approved) are limited The clinical significance of sermorelin-induced IGF-1 increases in elderly pop
mechanism · pending
, published in Clinical Interventions in Aging (Walker RF, 2006; PMID: 18046908): Review proposing sermorelin as a superior alternative to rhGH for adult-onset GH insufficiency, emphasizing preserved pituitary reserve and neuroendocrine feedback mechanisms.
safety · pending
Sermorelin stimulates pituitary GH mRNA transcription increasing pituitary reserve Maintains normal GH pulsatility through intact somatostatin feedback May be safer than exogenous rhGH due to self-regulating mechanism Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency , published in BioDrugs (Prakash A and Goa KL, 1999; PMID: 18031173): Comprehensive review of sermorelin for pediatric GH deficiency diagnosis and treatment, covering pharmacology, clinical efficacy, and tolerability.
dosing · pending
IV sermorelin 1 mcg/kg is a specific test for GH deficiency diagnosis SC 30 mcg/kg/day at bedtime effective for growth promotion in GHD children Significant increases in height velocity sustained during 12 months treatment Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women , publish
outcome · pending
ed in Journal of Clinical Endocrinology and Metabolism (Vittone J et al., 1997; PMID: 9005976): Prospective study examining effects of nightly GHRH(1-29) injections in healthy elderly subjects, demonstrating increases in IGF-1 and lean body mass markers.
outcome · pending
IGF-1 levels rose significantly by 2 weeks and remained elevated to 12 weeks IGFBP-3 and GH binding protein levels increased Nle27 substitution provided oxidation resistance improving stability Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity , published in Journal of Pediatric Endocrinology (Lanes R et al., 1993; PMID: 7955460): Clinical study demonstrating that GHRH(1-29) treatment produces sustained increases in growth velocity in children with idiopathic short stature.
safety · pending
Sustained increase in growth velocity achieved with daily GHRH(1-29) treatment Growth response maintained over the treatment period Good tolerability in pediatric population Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males , published in Translational Andrology and Urology (Siebert DM and Rao AL, 2020; PMID: 32257855): Review of GH secretagogues including sermorelin for body composition management, discussing mechanism differences and clinical applications.
dosing · pending
elease GH secretagogues may complement testosterone therapy for body composition Related Reading # Sermorelin research studies and evidence Sermorelin dosing protocols Sermorelin side effects profile GHRP-2 research guide Hexarelin research guide Stay current on Sermorelin research We summarize new studies, safety updates, and dosing insights — delivered biweekly.
regulatory · pending
Based on 120 + community reports View community protocols Frequently Asked Questions About Sermorelin Is sermorelin FDA approved?
regulatory · pending
Sermorelin was previously FDA-approved as Geref for diagnosing growth hormone deficiency, but the commercial product was discontinued.
regulatory · pending
The peptide itself is available through compounding pharmacies for off-label use under physician supervision.
Processing
Processed into 15 searchable sections.